How Does the Morbidity of Sore Throat in Recurrent Tonsillitis Correlate With the Tonsillitis Outcome Inventory‐14 ( TOI ‐14)?
Clinical Otolaryngology · 2026-09 · 51 (5) · 672-677
DOI: 10.1111/coa.70116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Otolaryngology, online erschienen am 11.05.2026. Verfasst von Pavithran Maniam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ear, Nose & Throat Department, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Tonsillitis, Pharyngitis, Tonsillectomy, Patient Reported Outcome Measures. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIHR Health Technology Assessment programme, Health Technology Assessment Programme.
Abstract (Originalsprache)
Introduction
The National Trial of Tonsillectomy in Adults (NATTINA) demonstrated that tonsillectomy is clinically and cost‐effective; however, the generalizability of the results to a real‐world population remains uncertain. The number of episodes of tonsillitis is used to assess candidacy for tonsillectomy. An alternative approach could be to utilise a patient‐reported outcome measure such as the Tonsillectomy Outcome Inventory‐14 (TOI‐14).
Aim
To compare the TOI‐14 scores in a real‐world clinical cohort with the NATTINA cohort. To assess the relationship between the TOI‐14 and the number of sore throat days. To assess the role of socioeconomic status in recurrent tonsillitis.
Methods
Baseline TOI‐14 scores, the relationship between the number of sore throat days and TOI‐14 scores, and socioeconomic deprivation were compared between a real‐world clinical cohort and the NATTINA population.
Results
Individuals declining entry into NATTINA ( n = 609) had the highest TOI‐14 score (48.3 (SD 9.9)), followed by the clinical cohort ( n = 422) (43.9 (SD 13.3)) and then the randomised NATTINA population ( n = 452) (43.1 (SD 12.0), p < 0.001). The correlation between the number of sore throat days and baseline TOI‐14 score in all participants was very weak, 0.114, p = 0.001. Approximately 50% of participants with recurrent tonsilitis reside in areas ranked from deciles 1 to 3 on the Scottish/English Index of Multiple Deprivation.
Conclusion
The findings from NATTINA can be applied to general clinical practice. The use of a patient‐reported outcome measurement instead of sore throat episodes as a criterion for tonsillectomy candidacy requires further research and should consider the impact of socioeconomic status on tonsillitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ear, Nose & Throat Department, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
- Department of Otolaryngology/ENT Surgery, NHS Greater Glasgow and Clyde, Glasgow, UK.
- Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
- Biostatistics Research Group, Newcastle University, Newcastle upon Tyne, UK.
Förderung
- NIHR Health Technology Assessment programme
- Health Technology Assessment Programme
Zitieren
APA
Maniam, P., Douglas, C. M., Fouweather, T., Teare, M. D., Wilson, J., & O'Hara, J. (2026). How Does the Morbidity of Sore Throat in Recurrent Tonsillitis Correlate With the Tonsillitis Outcome Inventory‐14 ( TOI ‐14)?. Clinical Otolaryngology, 51(5), 672-677. https://doi.org/10.1111/coa.70116
Vancouver
Maniam P, Douglas CM, Fouweather T, Teare MD, Wilson J, O'Hara J. How Does the Morbidity of Sore Throat in Recurrent Tonsillitis Correlate With the Tonsillitis Outcome Inventory‐14 ( TOI ‐14)?. Clinical Otolaryngology. 2026;51(5):672-677. doi:10.1111/coa.70116
BibTeX
@article{Maniam2026,
author = {Maniam, Pavithran and Douglas, Catriona M and Fouweather, Tony and Teare, M Dawn and Wilson, Janet and O'Hara, James},
title = {How Does the Morbidity of Sore Throat in Recurrent Tonsillitis Correlate With the Tonsillitis Outcome Inventory‐14 ( TOI ‐14)?},
journal = {Clinical Otolaryngology},
year = {2026},
volume = {51},
number = {5},
pages = {672--677},
doi = {10.1111/coa.70116}
}
EUVIMED